The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival
Open accessAbstract
Emerging evidences suggest the existence of a new mode of epidermal growth factor receptor (EGFR) signalling pathway in which activated EGFR undergoes nuclear translocalization and subsequently regulates gene expression and potentially mediates other cellular processes. This signalling route is distinct from the better-characterized, traditional EGFR pathway that involves transduction of mitogenic signals through activation of multiple signalling cascades. Transcriptional activity of nuclear EGFR appears to depend on its C-terminal transactivation domain and its physical and functional interaction with other transcription factors that contain DNA-binding activity. Likely via its ability to upregulate gene expression, nuclear EGFR pathway is associated with major characteristics of more aggressive tumours: increased proliferative potential, nitric oxide synthesis, and accelerated G1/S cell cycle progression. A role of nuclear EGFR in prognostic prediction is further suggested in patients with breast carcinomas and oropharyngeal squamous cell carcinomas. It is noted that significant advances were made towards the knowledge of the nuclear EGFR pathway; however, many aspects of this new pathway remain unresolved and will be discussed in this review. As a number of other receptor tyrosine kinases (RTKs) and cytokine receptors also undergo similar nuclear translocalization, a better understanding of the physiological and malignant nature of the nuclear EGFR pathway will likely shed light into the biology of cancer with nuclear RTKs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
Gupta, R. A., & DuBois, R. N. (2001) · Nature Reviews Cancer · doi:10.1038/35094017 · Cited by 1,066
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Self-citationγ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase
Ni, C.-Y., Murphy, M. P., Golde, T. E., & Carpenter, G. (2001) · Science · doi:10.1126/science.1065412 · Cited by 856
The role of nitric oxide in cancer
XU, W., LIU, L. Z., LOIZIDOU, M., AHMED, M., & CHARLES, I. G. (2002) · Cell Research · doi:10.1038/sj.cr.7290133 · Cited by 826
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., & Hung, M.-C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 544
Self-citationDittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
Komuro, A., Nagai, M., Navin, N. E., & Sudol, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305597200 · Cited by 456
VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells
Shay-Salit, A., Shushy, M., Wolfovitz, E., Yahav, H., Breviario, F., Dejana, E., & Resnick, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142224299 · Cited by 339
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.012 · Cited by 305
Self-citationNovel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 290
Self-citation
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Enuka, Y., Lauriola, M., Feldman, M. E., Sas-Chen, A., Ulitsky, I., & Yarden, Y. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1367 · Cited by 757
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Estrogen Signaling through the Transmembrane G Protein–Coupled Receptor GPR30
Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I., Sklar, L. A., & Hathaway, H. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100518 · Cited by 590
ErbB receptors: new insights on mechanisms and biology
LINGGI, B., & CARPENTER, G. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.10.008 · Cited by 377
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Tyrosine phosphorylation controls PCNA function through protein stability
Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Yang, C.-C., McIntush, E. W., Li, L.-Y., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Self-citationNuclear EGFR contributes to acquired resistance to cetuximab
Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L. (2009) · Oncogene · doi:10.1038/onc.2009.234 · Cited by 313
EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment
Liccardi, G., Hartley, J. A., & Hochhauser, D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2384 · Cited by 291
PCNA: a silent housekeeper or a potential therapeutic target?
Wang, S.-C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.02.004 · Cited by 285
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M.-C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 260
Self-citationTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Cancer prevention by tea: Evidence from laboratory studies
Yang, C. S., Wang, H., Li, G. X., Yang, Z., Guan, F., & Jin, H. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.03.001 · Cited by 258
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients
Glynn, S. A., Boersma, B. J., Dorsey, T. H., Yi, M., Yfantis, H. G., Ridnour, L. A., Martin, D. N., Switzer, C. H., Hudson, R. S., Wink, D. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42059 · Cited by 254
The role of the VEGF-C/VEGFR-3 axis in cancer progression
Su, J.-L., Yen, C.-J., Chen, P.-S., Chuang, S.-E., Hong, C.-C., Kuo, I.-H., Chen, H.-Y., Hung, M.-C., & Kuo, M.-L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603487 · Cited by 252
Self-citationCancer cell signaling pathways targeted by spice-derived nutraceuticals
Sung, B., Prasad, S., Yadav, V. R., & Aggarwal, B. B. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.630551 · Cited by 204
Convergence in parameters and predictions using computational experimental design
Hagen, D. R., White, J. K., & Tidor, B. (2013) · Interface Focus · doi:10.1098/rsfs.2013.0008 · Cited by 41
Metadata
- Authors
- Lo, H.-W., & Hung, M.-C.
- Venue
- British Journal of Cancer
- Published
- 2006-01
- Volume
- 94
- Issue
- 2
- Pages
- 184-188
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2005868479
- Cited by
- 323
- References
- 40
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.